Where does NEUP stock trade?

Neuphoria Therapeutics Inc. (NEUP) is listed on NASDAQ.

What sector and industry is NEUP in?

Neuphoria Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.

When did Neuphoria Therapeutics Inc. go public?

Neuphoria Therapeutics Inc. (NEUP) completed its IPO in 2021.

What companies are similar to NEUP?

Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NEUP side-by-side with any of them on Quantisnow.

How can I track NEUP on Quantisnow?

Quantisnow aggregates Neuphoria Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NEUP to receive live email and push alerts on every new disclosure.

NEUP

NASDAQ

Neuphoria Therapeutics Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2021

News25/Ratings0

Price$3.91-0.04 (-1.01%)

04:45 PM07:45 PM

News · 26 weeks7+200%

2026-02-082026-08-02

Mix690d

SEC Filings4(67%)
Other1(17%)
Offering1(17%)

Latest news

25 items

11dSEC
SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.
DEFA14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)
11dSEC
Neuphoria Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Changes in Control of Registrant, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Neuphoria Therapeutics Inc. (0001191070) (Filer)
12dPR
Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
All-share transaction creating a combined company to operate as Scancell advancing a pipeline of targeted, off-the-shelf, active immunotherapiesCombined company to be listed on Nasdaq, in addition to Scancell’s existing AIM listingAgreed pro forma merger ownership split: existing Scancell shareholders to own 85.5 per cent. of the combined company, with Neuphoria existing shareholders owning 14.5 per cent.1Financing to fund the global registrational Phase 3 trial for lead programme, iSCIB1+ active immunotherapy in advanced melanoma OXFORD, United Kingdom and BURLINGTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP) ("Scancell") and Neuphoria Therapeutics Inc. (
38dPR
Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc
Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to an announcement made by London-listed biotechnology company Scancell Holdings plc ("Scancell"). The Neuphoria Board notes the announcement made by Scancell earlier today about a possible combination with Neuphoria. The Scancell announcement was made follo
69dSEC
Neuphoria Therapeutics Inc. filed SEC Form 8-K: Other Events
8-K - Neuphoria Therapeutics Inc. (0001191070) (Filer)
80dSEC
SEC Form 10-Q filed by Neuphoria Therapeutics Inc.
10-Q - Neuphoria Therapeutics Inc. (0001191070) (Filer)
167dSEC
SEC Form 10-Q filed by Neuphoria Therapeutics Inc.
10-Q - Neuphoria Therapeutics Inc. (0001191070) (Filer)
194dINSIDER
SEC Form 4 filed by Director Wilson David Ian
4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)
194dINSIDER
SEC Form 4 filed by Director Davies Peter Miles Winston
4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)
194dINSIDER
SEC Form 4 filed by Director Fisher Alan
4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)
194dINSIDER
SEC Form 4 filed by Director Ryan Jane
4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)
217dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by Neuphoria Therapeutics Inc.
SCHEDULE 13D/A - Neuphoria Therapeutics Inc. (0001191070) (Subject)
228dSEC
Neuphoria Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K - Neuphoria Therapeutics Inc. (0001191070) (Filer)
229dSEC
Neuphoria Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
8-K - Neuphoria Therapeutics Inc. (0001191070) (Filer)
238dSEC
SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.
DEFA14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)
238dPR
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees
Company Urges Shareholders to Follow ISS' Recommendation and Vote the WHITE Proxy Card BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders Services ("ISS"), a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on the WHITE proxy card FOR BOTH of the Company's director nominees – Peter Miles Davies and David Wilson. As previously disclosed, Lynx1 Capital
242dSEC
SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.
DEFA14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)
242dPR
Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium
Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote "FOR" BOTH of Neuphoria's Nominees on the WHITE Proxy Card BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to dissident stockholder, Lynx1 Master Fund LP's ("Lynx1"), revised indication of interest to acquire the Company. Lynx1 Operating Outside Neuphoria's R
245dSEC
SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.
DEFA14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)
245dPR
Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions
BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statements to address what Neuphoria strongly believes is a campaign from Lynx1 Master Fund LP ("Lynx1") full of deception and distraction to deflect attention from its own limitations and its handpicked nominees' shortcomings. The Company urges stockholders to trust Neuphoria's commitment to transparency and value creation over what it believes are Lynx1's fabrications and misdire
251dSEC
SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.
DEFA14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)
252dSEC
SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.
DEFA14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)
252dSEC
SEC Form DEFC14A filed by Neuphoria Therapeutics Inc.
DEFC14A - Neuphoria Therapeutics Inc. (0001191070) (Subject)
252dPR
Neuphoria Therapeutics Inc. Sends Letter to Stockholders
Files Definitive Proxy Statement for 2025 Annual Meeting of Stockholders Urges Stockholders to Vote "FOR" BOTH Neuphoria Therapeutics Nominees on WHITE Proxy Card BURLINGTON, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company"), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued a letter to its stockholders regarding Neuphoria's 2025 Annual Meeting of Stockholders ("2025 Annual Meeting"), which is scheduled to be held on December 12, 2025. At the 2025 Annual Meeting, Neuphoria stockholders will have the opportunity to pro
262dSEC
SEC Form 424B5 filed by Neuphoria Therapeutics Inc.
424B5 - Neuphoria Therapeutics Inc. (0001191070) (Filer)

NEUP FAQ

5 questions

Where does NEUP stock trade?
Neuphoria Therapeutics Inc. (NEUP) is listed on NASDAQ.
What sector and industry is NEUP in?
Neuphoria Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
When did Neuphoria Therapeutics Inc. go public?
Neuphoria Therapeutics Inc. (NEUP) completed its IPO in 2021.
What companies are similar to NEUP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NEUP side-by-side with any of them on Quantisnow.
How can I track NEUP on Quantisnow?
Quantisnow aggregates Neuphoria Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NEUP to receive live email and push alerts on every new disclosure.